DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Exudative Age-related Macular Degeneration

Intervention: Macugen (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.

Clinical Details

Official title: A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration (AMD) In Real Life (Macureli Study).

Study design: Observational Model: Cohort

Primary outcome: Change From Baseline to Final Visit in Visual Acuity (VA) Score

Secondary outcome:

Number of Participants With Change in VA: Improvement

Number of Participants With Change in VA: Stabilization

Number of Participants With Change in VA: Worsening

Duration of Treatment

Frequency of Macugen Administration

Number of Participants Who Received Other Concomitant Age Related Macular Degeneration (AMD) Treatments

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients diagnosed with subfoveal neovascular (wet) age-related macular degeneration

- Patients having received at least 1 Macugen injection

- Treatment naive patients, or patients having received conventional therapy

- Patients having signed and dated informed consent.

Exclusion Criteria:

- Patients participating in another clinical study with Macugen.

Locations and Contacts

Pfizer Investigational Site, Aarschot 3200, Belgium

Pfizer Investigational Site, Deurne 2100, Belgium

Pfizer Investigational Site, Leuven 3000, Belgium

Pfizer Investigational Site, Liege 4000, Belgium

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: November 2007
Last updated: February 15, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017